ATE195123T1 - Pyrazolderivate und verfahren zu deren herstellung - Google Patents

Pyrazolderivate und verfahren zu deren herstellung

Info

Publication number: ATE195123T1
Authority: AT; Austria
Prior art keywords: pct; date oct; production; sec; formula
Prior art date: 1995-04-03

Application number

AT96909115T

Other languages

English (en)

Inventor

Peter Traxler

Pascal Furet

Guido Bold

Joerg Frei

Marc Lang

Original Assignee

Novartis Erfind Verwalt Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-03

Filing date

1996-03-22

Publication date

2000-08-15

1996-03-22 Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh

2000-08-15 Application granted granted Critical

2000-08-15 Publication of ATE195123T1 publication Critical patent/ATE195123T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT96909115T 1995-04-03 1996-03-22 Pyrazolderivate und verfahren zu deren herstellung ATE195123T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH93795		1995-04-03
CH42196		1996-02-16
PCT/EP1996/001263 WO1996031510A1 (en)	1995-04-03	1996-03-22	Pyrazole derivatives and processes for the preparation thereof

Publications (1)

Publication Number	Publication Date
ATE195123T1 true ATE195123T1 (de)	2000-08-15

Family

ID=25684532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96909115T ATE195123T1 (de)	1995-04-03	1996-03-22	Pyrazolderivate und verfahren zu deren herstellung

Country Status (13)

Country	Link
US (1)	US5981533A (de)
EP (1)	EP0819129B1 (de)
JP (1)	JP4249804B2 (de)
AT (1)	ATE195123T1 (de)
AU (1)	AU711592B2 (de)
CA (1)	CA2214086C (de)
DE (1)	DE69609602T2 (de)
DK (1)	DK0819129T3 (de)
ES (1)	ES2150113T3 (de)
GR (1)	GR3034415T3 (de)
NZ (1)	NZ304859A (de)
PT (1)	PT819129E (de)
WO (1)	WO1996031510A1 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW321649B (de) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
US5932574A (en) *	1995-04-27	1999-08-03	Zeneca Limited	Quinazoline derivatives
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
CZ1598A3 (cs) *	1995-07-06	1998-04-15	Novartis Ag	Pyrrolopyrimidiny a způsoby jejich přípravy
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
ATE217873T1 (de) *	1996-01-23	2002-06-15	Novartis Erfind Verwalt Gmbh	Pyrrolopyrimidinen und verfahren zu deren herstellung
CA2242425C (en)	1996-02-13	2006-07-18	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
DE69709319T2 (de)	1996-03-05	2002-08-14	Astrazeneca Ab, Soedertaelje	4-anilinochinazolin derivate
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
CA2262421C (en)	1996-08-23	2007-10-02	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
ID18494A (id) *	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
WO1998014449A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
WO1998014450A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
IL129825A0 (en)	1996-11-27	2000-02-29	Pfizer	Fused bicyclic pyrimidine derivatives
WO1999017769A1 (en) *	1997-10-06	1999-04-15	Basf Aktiengesellschaft	INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
JP2001518502A (ja)	1997-10-06	2001-10-16	ビーエーエスエフアクチェンゲゼルシャフト	チロシンキナーゼ活性を阻害するためのインデノ［１，２−ｃ］ピラゾール誘導体
DE69943144D1 (de)	1998-03-31	2011-03-03	Kyowa Hakko Kirin Co Ltd	Stickstoffenthaltende heterocyclische verbindungen
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
CN1390219A (zh) *	1999-09-17	2003-01-08	艾博特股份有限两合公司	作为治疗剂的吡唑并嘧啶类
JP3522727B2 (ja)	1999-11-05	2004-04-26	アストラゼネカアクチボラグ	Ｖｅｇｆ阻害剤としてのキナゾリン誘導体
DE60228103D1 (de) *	2001-10-02	2008-09-18	Smithkline Beecham Corp	Chemische verbindungen
JP4518378B2 (ja)	2001-10-29	2010-08-04	ベーリンガーインゲルハイムインテルナツィオナールゲゼルシャフトミットベシュレンクテルハフツング	エネルギー恒常性および細胞小器官代謝の調節に関与するＭｎｋキナーゼ相同性タンパク質
ES2303601T3 (es) *	2002-07-25	2008-08-16	Pfizer Italia S.R.L.	Derivados de pirazoles heterociclicos condensados como inhibidores de quinasas.
US20040121407A1 (en) *	2002-09-06	2004-06-24	Elixir Pharmaceuticals, Inc.	Regulation of the growth hormone/IGF-1 axis
WO2004106339A2 (en) *	2003-05-28	2004-12-09	Università Degli Studi Di Siena	4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
US7429596B2 (en) *	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
DE10356579A1 (de) *	2003-12-04	2005-07-07	Merck Patent Gmbh	Aminderivate
KR20070085340A (ko) *	2004-10-12	2007-08-27	디코드 제네틱스, 아이엔씨.	폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물
JP2008520744A (ja) *	2004-11-19	2008-06-19	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	抗炎症性ピラゾロピリミジン
US7947676B2 (en)	2004-12-14	2011-05-24	Astrazeneca Ab	Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
WO2007030582A2 (en) *	2005-09-09	2007-03-15	Bristol-Myers Squibb Company	Acyclic ikur inhibitors
JP2009529541A (ja)	2006-03-09	2009-08-20	ファーマコピアインコーポレーテッド	代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
PT2004654E (pt) *	2006-04-04	2013-08-27	Univ California	Derivados de pirazolopirimidina para utilização como antagonistas da quinase
WO2009046448A1 (en)	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
EP2240451B1 (de)	2008-01-04	2017-08-09	Intellikine, LLC	Durch Purin substituierte Isochinolinonderivate zur Verwendung als PI3K-Hemmer
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (de)	2008-03-14	2018-06-27	Intellikine, LLC	Kinasehemmer und verwendungsverfahren
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
KR20110039326A (ko)	2008-07-08	2011-04-15	인텔리카인, 인크.	키나제 억제제 및 사용 방법
US8703778B2 (en)	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
EP2358720B1 (de)	2008-10-16	2016-03-02	The Regents of The University of California	Heteroarylkinasehemmer mit kondensierten ringen
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
EP2349235A1 (de)	2008-11-07	2011-08-03	Triact Therapeutics, Inc.	Verwendung von catecholbutan-derivaten in der krebstherapie
JP2012518657A (ja)	2009-02-25	2012-08-16	オーエスアイ・ファーマシューティカルズ，エルエルシー	併用抗癌治療
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
EP2401614A1 (de)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
WO2010099364A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120064072A1 (en)	2009-03-18	2012-03-15	Maryland Franklin	Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
CA2760791C (en)	2009-05-07	2017-06-20	Intellikine, Inc.	Heterocyclic compounds and uses thereof
PE20170003A1 (es)	2009-08-17	2017-03-15	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
EP2510110A1 (de)	2009-11-13	2012-10-17	Pangaea Biotech S.L.	Molekulare biomarker zur vorhersage der reaktion auf tyrosinkinaseinhibitoren bei lungenkrebs
WO2011146882A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2468883A1 (de)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
MX347708B (es)	2011-01-10	2017-05-09	Infinity Pharmaceuticals Inc	Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
AR085397A1 (es)	2011-02-23	2013-09-25	Intellikine Inc	Combinacion de inhibidores de quinasa y sus usos
EP2492688A1 (de)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
CA2842190A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
EP2734520B1 (de)	2011-07-19	2016-09-14	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen und ihre verwendung
US8785470B2 (en)	2011-08-29	2014-07-22	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013033380A1 (en)	2011-08-31	2013-03-07	Genentech, Inc.	Diagnostic markers
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
CA2849120A1 (en)	2011-09-30	2013-04-18	Genentech, Inc.	Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en)	2012-09-26	2015-04-29	Univ California	Modulation of ire1
GB201223308D0 (en)	2012-12-21	2013-02-06	Univ Sunderland	Enzyme inhibitors
AU2014223548A1 (en)	2013-02-26	2015-10-15	Triact Therapeutics, Inc.	Cancer therapy
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US20160051556A1 (en)	2013-03-21	2016-02-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3044593A4 (de)	2013-09-09	2017-05-17	Triact Therapeutics, Inc.	Krebstherapie
TWI657085B (zh)	2013-10-04	2019-04-21	英菲尼提製藥股份有限公司	雜環化合物及其用途
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX2016012021A (es)	2014-03-19	2017-04-13	Infinity Pharmaceuticals Inc	Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
AR101106A1 (es) *	2014-07-02	2016-11-23	Pharmacyclics Llc	Inhibidores de tirosina quinasa de bruton
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20170095893A (ko)	2014-12-24	2017-08-23	제넨테크, 인크.	방광암에 대한 치료, 진단, 및 예후 방법
AU2016322552B2 (en)	2015-09-14	2021-03-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
CN109952306A (zh) *	2016-04-19	2019-06-28	加利福尼亚大学董事会	ErbB抑制剂及其用途
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
UA125216C2 (uk)	2016-06-24	2022-02-02	Інфініті Фармасьютікалз, Інк.	Комбінована терапія
NZ754994A (en)	2016-12-22	2022-12-23	Amgen Inc	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
AR112797A1 (es)	2017-09-08	2019-12-11	Amgen Inc	Inhibidores de kras g12c y métodos para utilizarlos
JP7266043B2 (ja)	2018-05-04	2023-04-27	アムジエン・インコーポレーテツド	ＫＲａｓＧ１２Ｃ阻害剤及びそれを使用する方法
MX2020011582A (es)	2018-05-04	2020-11-24	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
US10988485B2 (en)	2018-05-10	2021-04-27	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
MX2020012731A (es)	2018-06-01	2021-02-22	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
MX2020012204A (es)	2018-06-11	2021-03-31	Amgen Inc	Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
CN113194954A (zh)	2018-10-04	2021-07-30	国家医疗保健研究所	用于治疗角皮病的egfr抑制剂
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019384118A1 (en)	2018-11-19	2021-05-27	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
AU2019403488A1 (en)	2018-12-20	2021-06-24	Amgen Inc.	KIF18A inhibitors
UY38526A (es)	2018-12-20	2020-06-30	Amgen Inc	Inhibidores de kif18a
MX2021007157A (es)	2018-12-20	2021-08-16	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a.
US20220056015A1 (en)	2018-12-20	2022-02-24	Amgen Inc.	Kif18a inhibitors
WO2020180768A1 (en)	2019-03-01	2020-09-10	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
CN113727758A (zh)	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
EP3738593A1 (de)	2019-05-14	2020-11-18	Amgen, Inc	Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CA3225293A1 (en)	2019-05-21	2020-11-26	Amgen Inc.	Solid state forms
WO2021026101A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
JP2022542319A (ja)	2019-08-02	2022-09-30	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤
EP4007752A1 (de)	2019-08-02	2022-06-08	Amgen Inc.	Kif18a-inhibitoren
EP4007638A1 (de)	2019-08-02	2022-06-08	Amgen Inc.	Pyridinderivate als kif18a-inhibitoren
AU2020369569A1 (en)	2019-10-24	2022-04-14	Amgen Inc.	Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
TW202132315A (zh)	2019-11-04	2021-09-01	美商銳新醫藥公司	Ras 抑制劑
EP4055028A1 (de)	2019-11-04	2022-09-14	Revolution Medicines, Inc.	Ras-inhibitoren
CA3159561A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
JP2023500328A (ja)	2019-11-08	2023-01-05	レボリューションメディシンズインコーポレイテッド	二環式ヘテロアリール化合物及びその使用
EP4058432A1 (de)	2019-11-14	2022-09-21	Amgen Inc.	Verbesserte synthese einer kras-g12c-hemmenden verbindung
BR112022009390A2 (pt)	2019-11-14	2022-08-09	Amgen Inc	Síntese melhorada de composto inibidor de kras g12c
CN114980976A (zh)	2019-11-27	2022-08-30	锐新医药公司	共价ras抑制剂及其用途
JP2023509701A (ja)	2020-01-07	2023-03-09	レヴォリューション・メディスンズ，インコーポレイテッド	Ｓｈｐ２阻害剤投薬およびがんを処置する方法
IL299131A (en)	2020-06-18	2023-02-01	Revolution Medicines Inc	Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
EP4208261A1 (de)	2020-09-03	2023-07-12	Revolution Medicines, Inc.	Verwendung von sos1-inhibitoren zur behandlung von malignitäten mit shp2-mutationen
CA3194067A1 (en)	2020-09-15	2022-03-24	Revolution Medicines, Inc.	Ras inhibitors
US20240051956A1 (en)	2020-12-22	2024-02-15	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
CN118852330A (zh)	2021-05-05	2024-10-29	锐新医药公司	用于治疗癌症的ras抑制剂
WO2022235866A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
EP4334321A1 (de)	2021-05-05	2024-03-13	Revolution Medicines, Inc.	Ras-inhibitoren
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023114954A1 (en)	2021-12-17	2023-06-22	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (de)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024081916A1 (en)	2022-10-14	2024-04-18	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
US20240352036A1 (en)	2023-04-14	2024-10-24	Revolution Medicines, Inc.	Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216048A1 (en)	2023-04-14	2024-10-17	Revolution Medicines, Inc.	Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
CN117865965B (zh) *	2024-01-08	2024-06-28	贵州省天然产物研究中心	吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69222637T2 (de) *	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
WO1996040142A1 (en) *	1995-06-07	1996-12-19	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
WO1998014450A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
WO1998014449A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
EP0929645A1 (de) *	1996-10-04	1999-07-21	The Procter & Gamble Company	Verfahren zur herstellung einer waschmittelzusammensetzung mit niedrigem schüttgewicht durch prozess ohne turm

1996
- 1996-03-22 AT AT96909115T patent/ATE195123T1/de active
- 1996-03-22 US US08/930,904 patent/US5981533A/en not_active Expired - Lifetime
- 1996-03-22 ES ES96909115T patent/ES2150113T3/es not_active Expired - Lifetime
- 1996-03-22 NZ NZ304859A patent/NZ304859A/xx not_active IP Right Cessation
- 1996-03-22 WO PCT/EP1996/001263 patent/WO1996031510A1/en active IP Right Grant
- 1996-03-22 CA CA002214086A patent/CA2214086C/en not_active Expired - Fee Related
- 1996-03-22 DE DE69609602T patent/DE69609602T2/de not_active Expired - Lifetime
- 1996-03-22 JP JP52992996A patent/JP4249804B2/ja not_active Expired - Fee Related
- 1996-03-22 PT PT96909115T patent/PT819129E/pt unknown
- 1996-03-22 AU AU52733/96A patent/AU711592B2/en not_active Ceased
- 1996-03-22 DK DK96909115T patent/DK0819129T3/da active
- 1996-03-22 EP EP96909115A patent/EP0819129B1/de not_active Expired - Lifetime
2000
- 2000-09-15 GR GR20000402103T patent/GR3034415T3/el unknown

Also Published As

Publication number	Publication date
US5981533A (en)	1999-11-09
DK0819129T3 (da)	2000-10-23
CA2214086A1 (en)	1996-10-10
DE69609602D1 (de)	2000-09-07
EP0819129B1 (de)	2000-08-02
PT819129E (pt)	2001-01-31
ES2150113T3 (es)	2000-11-16
AU5273396A (en)	1996-10-23
EP0819129A1 (de)	1998-01-21
JP4249804B2 (ja)	2009-04-08
GR3034415T3 (en)	2000-12-29
JPH11502859A (ja)	1999-03-09
WO1996031510A1 (en)	1996-10-10
DE69609602T2 (de)	2001-04-12
AU711592B2 (en)	1999-10-14
CA2214086C (en)	2008-07-29
NZ304859A (en)	2000-01-28

Publication	Publication Date	Title
ATE195123T1 (de)	2000-08-15	Pyrazolderivate und verfahren zu deren herstellung
DE69619114D1 (de)	2002-03-21	Pyrolopyrimidine und verfahren zu ihrer herstellung
DE69732780D1 (de)	2005-04-21	Pyrimiderivate und verfahren zu ihrer herstellung
ATE208778T1 (de)	2001-11-15	Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung
PT938486E (pt)	2008-03-27	Pirrolopirimidinas substituídas e processos para a sua preparação
BR0014973A (pt)	2002-07-16	Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
MD1632F2 (en)	2001-03-31	Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals
DE59710417D1 (de)	2003-08-14	N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
HU0103927D0 (en)	2001-12-28	Intermediates of pyrrolo[2,3-d]pyrimidine derivatives and process for the preparation thereof
ATE179420T1 (de)	1999-05-15	Pyrimido (5,4-d>pyrimidine, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE215088T1 (de)	2002-04-15	Pyrrolo(3,4-d)pyrimidinon-derivate und ihre verwendung als immunosuppressoren
DE69308029D1 (de)	1997-03-20	1,2,3,5,6,7,8,8a-OCTAHYDRO-5,5,8a-TRIMETHYL-(8aBETA)-6-ISOCHINOLINAMINE-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS THERAPEUTIKA
ATE205837T1 (de)	2001-10-15	Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung
BR9607335A (pt)	1997-11-25	Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
ATE304541T1 (de)	2005-09-15	Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte
DE59607683D1 (de)	2001-10-18	Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE69943259D1 (de)	2011-04-21	Neue 2-Halogen-Derivate von 5-O-Desosaminylerythronolid A, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AT388553B (de)	1989-07-25	1-substituierte 3-aryl-7-chlor-3,4-dihydro(2h)acridon-n-oxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel und futtermittelzusatz
DE3669151D1 (de)	1990-04-05	Verfahren zur herstellung von 2-acyl-3,4-alkoxyanilinen.
DE3576822D1 (de)	1990-05-03	Pyrrolo(1,2-b)(1,2,5)triazepine, verfahren und zwischenprodukte zu ihrer herstellung und ihre anwendung als arzneimittel.
ATE36337T1 (de)	1988-08-15	Ethyl-benzylphosphinat-derivate, verfahren zu ihrer herstellung und ihre verwendung als calcium-antagonisten.
DE3667464D1 (de)	1990-01-18	Verfahren zur herstellung von 2-acyl-3,4-dialkoxyanilinen.
MX9606166A (es)	1998-01-31	Pirazoles substituidos.

Legal Events

Date	Code	Title	Description
2001-01-15	UEP	Publication of translation of european patent specification